- Home
- KXIN vs GTBP Comparison
KXIN vs GTBP Comparison
Compare KXIN & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KXIN | GTBP |
|---|---|---|
| Founded | 2015 | 1965 |
| Country | China | United States |
| Employees | 13 | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 8.8M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | KXIN | GTBP |
|---|---|---|
| Price | $6.01 | $0.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 424.0K | ★ 1.9M |
| Earning Date | 11-26-2019 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $0.26 |
| 52 Week High | $22.00 | $3.73 |
Technical Indicators
Market Signals| Indicator | KXIN | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 61.11 |
| Support Level | $5.30 | $0.39 |
| Resistance Level | $5.86 | $0.79 |
| Average True Range (ATR) | 0.54 | 0.06 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 69.63 | 95.46 |
Price Performance
Historical ComparisonAbout KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.